The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract pharmacy arrangements. The two companies were also denied a preliminary injunction in Maine last week.

Judge John McConnell Jr. delivered the order from the bench. “The drug manufacturers have tested other similar state statutes through lawsuits and requests for injunctive relief based on the same or similar legal claims,” he said. “This court has reviewed the statutes, case law, the parties’ briefs, as well as amicus briefs. Based on its own reasoning and that of its sister courts, the court agrees that the plaintiffs are not likely to succeed on the merits of their claim.” 

The AHA filed amicus briefs (AbbVie, Novartis) in these cases opposing the drug companies’ motions and has opposed similar challenges by drug companies in multiple states.

Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…